PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32180118-0 2020 Ruxolitinib treatment of a patient with steroid-dependent severe autoimmunity due to STAT1 gain-of-function mutation. ruxolitinib 0-11 signal transducer and activator of transcription 1 Homo sapiens 85-90 32180118-2 2020 We report the effect of oral ruxolitinib, an inhibitor of Janus kinase (JAK) family tyrosine kinases, on the clinical and immune status of a 3-year-old male with steroid-dependent severe autoimmunity due to a STAT1 GOF T385M mutation. ruxolitinib 29-40 signal transducer and activator of transcription 1 Homo sapiens 209-214 31512162-0 2019 Novel Gain-of-Function Mutation in Stat1 Sumoylation Site Leads to CMC/CID Phenotype Responsive to Ruxolitinib. ruxolitinib 99-110 signal transducer and activator of transcription 1 Homo sapiens 35-40 32758351-6 2020 Chemical inhibition of JAK1 in COV434 cells with 100nM ruxolitinib for 72h resulted in significant increases in STAT3 mRNA (P=0.034) and p-Y701-STAT1 protein (P=0.0117), demonstrating a role for JAK1 in modulating STAT in granulosa cells. ruxolitinib 55-66 signal transducer and activator of transcription 1 Homo sapiens 144-149 32492985-0 2020 The Dose Dependent Effects of Ruxolitinib on the Invasion and Tumorigenesis in Gliomas Cells via Inhibition of Interferon Gamma-Depended JAK/STAT Signaling Pathway. ruxolitinib 30-41 signal transducer and activator of transcription 1 Homo sapiens 141-145 32492985-3 2020 This study aimed to determine the dose-dependent effects of ruxolitinib, an inhibitor of JAK, on the interferon (IFN)-I/IFN-alpha/IFN-beta receptor/STAT and IFN-gamma/IFN-gamma receptor/STAT1 axes of the IFN-receptor-dependent JAK/STAT signaling pathway in glioblastoma invasion and tumorigenesis in U87 glioblastoma tumor spheroids. ruxolitinib 60-71 signal transducer and activator of transcription 1 Homo sapiens 148-152 32492985-3 2020 This study aimed to determine the dose-dependent effects of ruxolitinib, an inhibitor of JAK, on the interferon (IFN)-I/IFN-alpha/IFN-beta receptor/STAT and IFN-gamma/IFN-gamma receptor/STAT1 axes of the IFN-receptor-dependent JAK/STAT signaling pathway in glioblastoma invasion and tumorigenesis in U87 glioblastoma tumor spheroids. ruxolitinib 60-71 signal transducer and activator of transcription 1 Homo sapiens 167-191 32492985-3 2020 This study aimed to determine the dose-dependent effects of ruxolitinib, an inhibitor of JAK, on the interferon (IFN)-I/IFN-alpha/IFN-beta receptor/STAT and IFN-gamma/IFN-gamma receptor/STAT1 axes of the IFN-receptor-dependent JAK/STAT signaling pathway in glioblastoma invasion and tumorigenesis in U87 glioblastoma tumor spheroids. ruxolitinib 60-71 signal transducer and activator of transcription 1 Homo sapiens 186-190 32492985-7 2020 Additionally, we showed that ruxolitinib inhibited phosphorylation of JAK/STAT proteins. ruxolitinib 29-40 signal transducer and activator of transcription 1 Homo sapiens 74-78 32492985-8 2020 The inhibition of IFNs dependent JAK/STAT signaling by ruxolitinib leads to decreases of the U87 cells invasiveness and tumorigenesis. ruxolitinib 55-66 signal transducer and activator of transcription 1 Homo sapiens 37-41 32492985-9 2020 We demonstrate that ruxolitinib may inhibit glioma invasion and tumorigenesis through inhibition of the IFN-induced JAK/STAT signaling pathway. ruxolitinib 20-31 signal transducer and activator of transcription 1 Homo sapiens 120-124 32492985-10 2020 Conclusion: Collectively, our results revealed that ruxolitinib may have therapeutic potential in glioblastomas, possibly by JAK/STAT signaling triggered by IFN-alpha and IFN-gamma. ruxolitinib 52-63 signal transducer and activator of transcription 1 Homo sapiens 129-133 30622322-10 2019 The addition of ruxolitinib inhibited STAT1 phosphorylation and to a lesser extent STAT3 phosphorylation. ruxolitinib 16-27 signal transducer and activator of transcription 1 Homo sapiens 38-43 32698510-13 2020 Ruxolitinib suppressed the phosphorylation of JAK1, JAK2 and JAK3, and STAT1 and 3 compared to IFN-gamma pretreated hDPCs. ruxolitinib 0-11 signal transducer and activator of transcription 1 Homo sapiens 71-82 32698510-15 2020 In conclusion, ruxolitinib modulated and reverted the interferon-induced inflammatory changes by blocking the JAK-STAT pathway in hDPCs under an AA-like environment. ruxolitinib 15-26 signal transducer and activator of transcription 1 Homo sapiens 114-118 30035369-9 2018 Moreover, STAT1 knockdown significantly reduced EGF-mediated PD-L1 expression, and ruxolitinib, a JAK1/JAK2 inhibitor, significantly inhibited STAT1 phosphorylation to reduce the IFNr-mediated PD-L1 axis. ruxolitinib 83-94 signal transducer and activator of transcription 1 Homo sapiens 143-148 31182137-14 2019 Transcriptome analyses revealed that STAT1 and STAT3 activation enable AKR1C1-induced cisplatin-resistance and can be overcome by ruxolitinib treatment. ruxolitinib 130-141 signal transducer and activator of transcription 1 Homo sapiens 37-42 30030153-5 2019 After intermittent UVB exposure, melanocytes treated with the JAK inhibitor ruxolitinib reduced expression of HMGB1 and MX1 as well as activation of JAK1 (pJAK1) and signal transducer and activator of transcription 1 (pSTAT1). ruxolitinib 76-87 signal transducer and activator of transcription 1 Homo sapiens 166-216 30655323-8 2019 In vivo, estrogen and ruxolitinib significantly reduced tumor size and decreased expression of MUC1, P-STAT1, and IFITM1. ruxolitinib 22-33 signal transducer and activator of transcription 1 Homo sapiens 103-108 29934865-0 2018 Utility of Ruxolitinib in a Child with Chronic Mucocutaneous Candidiasis Caused by a Novel STAT1 Gain-of-Function Mutation. ruxolitinib 11-22 signal transducer and activator of transcription 1 Homo sapiens 91-96 30224514-6 2018 IFN-lambda receptor 1 knockdown and a JAK inhibitor, ruxolitinib, attenuated polyI:C-induced IFN-lambda expression, confirming that a positive autocrine feedback loop, the IFN-lambda receptor-JAK-STAT pathway, was involved in IFN-lambda expression. ruxolitinib 53-64 signal transducer and activator of transcription 1 Homo sapiens 196-200 29934865-2 2018 We aim to report the effect of oral ruxolitinib, the Janus kinase (JAK) family tyrosine kinase inhibitor, on clinical and immune status of a 12-year-old boy with severe CMC due to a novel STAT1 GOF mutation. ruxolitinib 36-47 signal transducer and activator of transcription 1 Homo sapiens 188-193 29934865-6 2018 RESULTS: A novel STAT1 GOF mutation (c.617T > C; p.L206P), detected in a child with recalcitrant CMC, was shown to be reversible in vitro with ruxolitinib. ruxolitinib 143-154 signal transducer and activator of transcription 1 Homo sapiens 17-22 29934865-8 2018 Clinical relapse and spike of all monitored phosphorylated STAT activity was registered shortly after unplanned withdrawal, decreasing again after ruxolitinib reintroduction. ruxolitinib 147-158 signal transducer and activator of transcription 1 Homo sapiens 59-63 29226168-0 2017 Risks of Ruxolitinib in STAT1 Gain-of-Function-Associated Severe Fungal Disease. ruxolitinib 9-20 signal transducer and activator of transcription 1 Homo sapiens 24-29 29111217-0 2018 Ruxolitinib partially reverses functional natural killer cell deficiency in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations. ruxolitinib 0-11 signal transducer and activator of transcription 1 Homo sapiens 90-140 29111217-0 2018 Ruxolitinib partially reverses functional natural killer cell deficiency in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations. ruxolitinib 0-11 signal transducer and activator of transcription 1 Homo sapiens 142-147 29111217-7 2018 NK cells from patients with STAT1 GOF mutations were treated in vitro with ruxolitinib. ruxolitinib 75-86 signal transducer and activator of transcription 1 Homo sapiens 28-33 29111217-11 2018 Upstream inhibition of STAT1 signaling with the small-molecule Janus kinase 1/2 inhibitor ruxolitinib in vitro and in vivo restored perforin expression in CD56dim NK cells and partially restored NK cell cytotoxic function. ruxolitinib 90-101 signal transducer and activator of transcription 1 Homo sapiens 23-28 29111217-13 2018 Modulation of increased STAT1 phosphorylation with ruxolitinib is an important option for therapeutic intervention in patients with STAT1 GOF mutations. ruxolitinib 51-62 signal transducer and activator of transcription 1 Homo sapiens 24-29 29111217-13 2018 Modulation of increased STAT1 phosphorylation with ruxolitinib is an important option for therapeutic intervention in patients with STAT1 GOF mutations. ruxolitinib 51-62 signal transducer and activator of transcription 1 Homo sapiens 132-137 29226168-2 2017 We describe therapeutic failures with the Janus Kinase (JAK) inhibitor ruxolitinib in 2 STAT1 GOF patients with severe invasive or cutaneous fungal infections. ruxolitinib 71-82 signal transducer and activator of transcription 1 Homo sapiens 88-93 34943910-5 2021 STAT1 and STAT2 were identified as being significantly overexpressed in the LFS patient, indicating ruxolitinib, a Janus kinase 1 and 2 inhibitors, as a potential therapy. ruxolitinib 100-111 signal transducer and activator of transcription 1 Homo sapiens 0-5 26787170-0 2016 Ruxolitinib Induces Interleukin 17 and Ameliorates Chronic Mucocutaneous Candidiasis Caused by STAT1 Gain-of-Function Mutation. ruxolitinib 0-11 signal transducer and activator of transcription 1 Homo sapiens 95-100 25662309-0 2015 Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation. ruxolitinib 7-18 signal transducer and activator of transcription 1 Homo sapiens 102-152 25662309-0 2015 Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation. ruxolitinib 7-18 signal transducer and activator of transcription 1 Homo sapiens 154-159 28139313-0 2017 Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation. ruxolitinib 0-11 signal transducer and activator of transcription 1 Homo sapiens 102-152 28139313-0 2017 Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation. ruxolitinib 0-11 signal transducer and activator of transcription 1 Homo sapiens 154-159 28139313-3 2017 OBJECTIVE: We sought to define the effect of increased STAT1 activity on T helper cell polarization and to investigate the therapeutic potential of ruxolitinib in treating autoimmunity secondary to STAT1 GOF mutations. ruxolitinib 148-159 signal transducer and activator of transcription 1 Homo sapiens 198-203 27379765-12 2016 They also exhibited increased IFN-beta and -gamma-induced STAT1 phosphorylation that was reversed upon treatment with the JAK kinase inhibitor ruxolitinib. ruxolitinib 143-154 signal transducer and activator of transcription 1 Homo sapiens 58-63 35371054-4 2022 Interferon (IFN)-gamma induces IDO1 expression through the Jak/STAT1 pathway and mediates Kyn production concomitantly with Trp consumption in CLL-conditioned media, while INCB018424 (ruxolitinib), a JAK1/2 inhibitor, impaired both effects. ruxolitinib 172-182 signal transducer and activator of transcription 1 Homo sapiens 63-68 34771447-5 2021 IFN-beta exposure induced apoptosis in GSCs with intrinsically high IFN/STAT1 signaling, and this effect was abolished by the pharmacological inhibitor ruxolitinib and STAT1 knockdown. ruxolitinib 152-163 signal transducer and activator of transcription 1 Homo sapiens 72-77 34109505-0 2021 SARS-CoV-2 infection in a pediatrics STAT1 GOF patient under Ruxolitinib therapy-a matter of balance? ruxolitinib 61-72 signal transducer and activator of transcription 1 Homo sapiens 37-42 35507130-3 2022 We here assessed the impact of ruxolitinib on the JAK-STAT1/3 pathway in DN STAT3 patients" cells. ruxolitinib 31-42 signal transducer and activator of transcription 1 Homo sapiens 54-61 35507130-5 2022 We also describe the impact of ruxolitinib on cytokine-induced STAT1 signaling in these patients. ruxolitinib 31-42 signal transducer and activator of transcription 1 Homo sapiens 63-68 35507130-8 2022 Ex vivo treatment with the JAK1/2-inhibitor ruxolitinib reduced cytokine responsiveness and normalized STAT1 phosphorylation in DN STAT3 and STAT1 GOF patient" cells. ruxolitinib 44-55 signal transducer and activator of transcription 1 Homo sapiens 103-108 35507130-8 2022 Ex vivo treatment with the JAK1/2-inhibitor ruxolitinib reduced cytokine responsiveness and normalized STAT1 phosphorylation in DN STAT3 and STAT1 GOF patient" cells. ruxolitinib 44-55 signal transducer and activator of transcription 1 Homo sapiens 141-146 35371054-4 2022 Interferon (IFN)-gamma induces IDO1 expression through the Jak/STAT1 pathway and mediates Kyn production concomitantly with Trp consumption in CLL-conditioned media, while INCB018424 (ruxolitinib), a JAK1/2 inhibitor, impaired both effects. ruxolitinib 184-195 signal transducer and activator of transcription 1 Homo sapiens 63-68 33965175-13 2021 Comparative analysis with PBMCs has demonstrated that MSCs are as equal as to HLADR+ PBMC populations in responding to ruxolitinib-mediated inhibition of IFNgamma-induced STAT-1 phosphorylation. ruxolitinib 119-130 signal transducer and activator of transcription 1 Homo sapiens 171-177 33965175-1 2021 Ruxolitinib is a JAK2/JAK1 inhibitor that blocks the inflammatory JAK-STAT signaling pathway. ruxolitinib 0-11 signal transducer and activator of transcription 1 Homo sapiens 70-74 33965175-8 2021 Human bone marrow derived MSCs, peripheral blood mononuclear cells (PBMCs), and primary bone marrow aspirates were analyzed for their sensitivity to ruxolitinib-mediated blocking of IFNgamma-induced STAT-1 phosphorylation and downstream effector molecules, utilizing Western blot, flow cytometry, secretome analysis, and phosflow techniques. ruxolitinib 149-160 signal transducer and activator of transcription 1 Homo sapiens 199-205 33965175-10 2021 Ruxolitinib inhibits IFNgamma and secretome of activated peripheral PBMC-induced STAT-1 phosphorylation on human bone marrow derived MSCs. ruxolitinib 0-11 signal transducer and activator of transcription 1 Homo sapiens 81-87 33475942-0 2021 Stepwise Reversal of Immune Dysregulation Due to STAT1 Gain-of-Function Mutation Following Ruxolitinib Bridge Therapy and Transplantation. ruxolitinib 91-102 signal transducer and activator of transcription 1 Homo sapiens 49-54 33475942-3 2021 Herein, we aimed to unravel the effect of ruxolitinib as a bridge therapy in a patient with sporadic STAT1 T385M mutation to manage infections and other disease manifestations. ruxolitinib 42-53 signal transducer and activator of transcription 1 Homo sapiens 101-106 33475942-8 2021 Dysregulation in STAT1 phosphorylation kinetics improved with ruxolitinib treatment and was completely normalized after transplantation. ruxolitinib 62-73 signal transducer and activator of transcription 1 Homo sapiens 17-22 33747209-0 2021 Ruxolitinib induces apoptosis of human colorectal cancer cells by downregulating the JAK1/2-STAT1-Mcl-1 axis. ruxolitinib 0-11 signal transducer and activator of transcription 1 Homo sapiens 92-97 33747209-6 2021 Firstly, JAK1/2-STAT1 was identified as the target of ruxolitinib. ruxolitinib 54-65 signal transducer and activator of transcription 1 Homo sapiens 16-21 33747209-10 2021 Taken together, the results showed that ruxolitinib decreased JAK1/2-STAT1-Mcl-1 protein level and effectively suppressed CRC cell proliferation in vitro and in vivo. ruxolitinib 40-51 signal transducer and activator of transcription 1 Homo sapiens 69-74 33965175-14 2021 Ex vivo analysis of human marrow aspirates has demonstrated that ruxolitinib blocks IFNgamma-induced STAT-1 phosphorylation in CD45+/-HLADR+/- populations at different levels, which is depending on their sensitivity to IFNgamma responsiveness. ruxolitinib 65-76 signal transducer and activator of transcription 1 Homo sapiens 101-107 33517393-10 2021 Given our results and the recent reports of ruxolitinib and tofacitinib use for the treatment of diseases caused by direct activation of STAT3 or STAT1 we speculate that these drugs may be effective in the treatment of our patient"s condition. ruxolitinib 44-55 signal transducer and activator of transcription 1 Homo sapiens 146-151 33501441-7 2021 JAK inhibitor ruxolitinib ablated STAT1 and dACE2 expression after interferon treatment. ruxolitinib 14-25 signal transducer and activator of transcription 1 Homo sapiens 34-39 32732635-0 2020 Ruxolitinib Response in an Infant with Very-Early-Onset Inflammatory Bowel Disease and Gain-of-Function STAT1 Mutation. ruxolitinib 0-11 signal transducer and activator of transcription 1 Homo sapiens 104-109